^
Association details:
| Biomarker: | FOXP3 overexpression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | Aqupla (nedaplatin) (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial
Published date:
06/27/2023
Excerpt:
Of 49 eligible patients, 33 underwent surgery with pCR rate of 30.1%. For the whole cohort, the median overall survival (OS) was 22.2 months....And, higher FOXP3 expression before (HR 0.14 ,95%CI 0.02- 1.29, log rank ¼0.045) and after (HR 0.29 ,95%CI 0.08-1.08, log rank p¼0.050) CRT contributed to favorable outcomes...Concurrent nedaplatin plus paclitaxel with radiotherapy was a promising induction regimen. Higher FOXP3 expression...were associated with favorable efficacy of neoadjuvant CRT.
Secondary therapy:
paclitaxel
DOI:
10.1016/j.annonc.2023.04.116
